Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 34Burkitt Lymphoma 33Lymphoma 31Leukemia, Myeloid, Acute 30Lymphoma, Non-Hodgkin 29Recurrence 26Breast Neoplasms 26Lymphoma, B-Cell 24Neoplasms 22Lymphoma, Follicular 22Leukemia, Lymphocytic, Chronic, B-Cell 22Myelodysplastic Syndromes 21Hodgkin Disease 18Triple Negative Breast Neoplasms 16Ovarian Neoplasms 16Leukemia 16Hematologic Neoplasms 15Melanoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Neuroblastoma 13Lymphoma, Mantle-Cell 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Pancreatic Neoplasms 11Leukemia, Biphenotypic, Acute 11Lymphoma, B-Cell, Marginal Zone 10Sarcoma 9Neoplasm Metastasis 9Leukemia, Myelomonocytic, Chronic 9

Interventions

Oxaliplatin 9Capecitabine 9Paclitaxel 7Fluorouracil 7pembrolizumab 6Leucovorin 6Cisplatin 5zolbetuximab 4Docetaxel 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Nivolumab 3Irinotecan 3Gemcitabine 3Albumin-Bound Paclitaxel 3fludarabine 2darolutamide 2atezolizumab 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Pemetrexed 2Cyclophosphamide 2Carboplatin 2130-nm albumin-bound paclitaxel 2vistusertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma × Cyclophosphamide × 90 days × Clear all
NCT02133196 2026-06-05

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
85 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis, Carcinoma, Adenosquamous

NCT05922930 2026-05-06

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
51 enrolled
GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡